Insulin therapy in AMI is associated with a 30% relative risk reduction in 1‐year mortality, as was demonstrated by Diabetes and Insulin‐Glucose infusion in Acute Myocardial Infarction (DIGAMI) trial (Malmberg et al., 1995). This evidence concerns the gene INS and diabetes mellitus.